An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.

A recent study published in the journal eLife has revealed significant links between blood types and the risk of developing ...

Humans are the only mammals with long hair on their heads. Scientists look into what drives this unique feature.

Using the improved technique, McCurry found that certain glucocorticoids are more abundant in human bile than others. The ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

A treatment that could potentially slow the progression of amyotrophic lateral sclerosis (ALS) is being studied at the Montreal Neurological Institute-Hospital. Dr. Olivier Blanchard and his team want ...

eLife is pleased to announce Timothy (Tim) Behrens as its new Editor-in-Chief to lead the initiative’s efforts to transform research communication. Behrens, Professor of Computational Neuroscience at ...

Neurology is a medical specialty that is concerned with the study of structure, function and disorders of the nervous system. Training a model on fetal and paediatric magnetic resonance images ...

RBC Capital analyst Shagun Singh said the deal fit strategically into J&J's neurological drugs division, an important area for the company. Sales of J&J's neurological drugs But at least one ...

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...

as well as SAGE-324 in essential tremor and other neurological disorders. The blockbuster deal featured an upfront payment of $875 million from Biogen and a $650 million equity investment in Sage.

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics.